Search | Clinical Trials Finder

Conditions: Heart Failure, Congestive
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Placebo, Saline; Drug
Lead sponsor: Horng Chen; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
Interventions: AI-enabled ECG-based Screening Tool; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congestive Heart Failure, Left Ventricular (LV) Systolic Dysfunction
Interventions: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT); Device
Lead sponsor: CardioKinetix, Inc; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Cardiomyopathy Due to Drug, Heart Failure, Systolic
Interventions: Lisinopril, Placebo Oral Tablet; Drug
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Peripartum Cardiomyopathy, Diastolic Dysfunction
Interventions: A clinical Transthoracic echocardiogram; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions: Not listed
Lead sponsor: Seattle Institute for Cardiac Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions: Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 99 more

Conditions: Left Ventricular Systolic Dysfunction
Interventions: AI-ECG; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure, Congestive, Myocardial Infarction, Ventricular Dysfunction, Left
Interventions: Not listed
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 34,810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 144
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 121 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions: Levosimendan, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more

Conditions: Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 254
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more

Conditions: Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Interventions: regadenoson; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Heart Failure
Interventions: Rexlemestrocel-L, Sham Comparator; Biological · Other
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 56
States / cities: Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 11 more

Conditions: Myocardial Ischemia, Left Ventricular Systolic Dysfunction, Elevated Cardiac Enzymes
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Conditions: Heart Failure
Interventions: CK-1827452; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Conditions: Heart Failure
Interventions: Placebo, Omecamtiv mecarbil; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Search by objective public record fields.

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

ECG AI-Guided Screening for Low Ejection Fraction

A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

SCD-HeFT 10 Year Follow-up

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

The Product Surveillance Registry REVERSE Post Approval Study

The SMART-LV Pilot Study

IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Pediatric Cardiomyopathy Mutation Analysis

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics